Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Lemonade Inc (LMND) vs Tilray Brands Inc (TLRY) Price & Performance

Lemonade IncTrade
Tilray Brands IncTrade

Price performance (Past 24H)

Key statistics

Lemonade Inc vs Tilray Brands Inc — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Lemonade Inc is far larger — about 6.8× Tilray Brands Inc's market cap, and Tilray Brands Inc is more actively traded (9,099,075 versus 1,544,794). Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Tilray Brands Inc for 31 Days on average.

LMNDTLRY
Market Cap
$3.63B$530.54M
Volume
1,544,7949,099,075
Sector
FinancialsHealth
52-Week High
$96.57$17.20
52-Week Low
$43.91$3.54
Typical Hold Time
27 Days31 Days
Enterprise Value
$3.49B$684.46M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Lemonade Inc

Lemonade (LMND) trades at $46.91, showing modest daily gains of 0.17%. The stock faces bearish technical signals despite recent earnings beats, with revenue growth accelerating to 32% year-over-year in Q2 2026. The company demonstrates improving fundamentals with gross profit margin at 47.85% and narrowing losses, targeting EBITDA profitability by late 2026. Recent expansion into Alaska and Kentucky markets supports growth trajectory.

Lemonade presents a growth story with improving margins and AI-driven efficiency, but profitability remains elusive. The 33% upside to consensus price target of $67 offers potential reward, though persistent losses and competitive pressures pose significant risks. Investors must weigh the company's expansion momentum against its negative cash flow from operations and high valuation multiples.

Tilray Brands Inc

Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.

TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

LMND

No sentiment data available yet.

TLRY
54% Buy46% Sell
Avg holding period · 31 Days

Top news

Latest headlines on both assets

About Lemonade Inc

Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.

Read more on LMND →

About Tilray Brands Inc

Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.

Read more on TLRY →